Loading clinical trials...
Loading clinical trials...
A Phase Ⅲ Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Ilaprazole (20mg QD) in Adult Patients With Erosive Esophagitis
This study compared Ilaprazole 20mg with lansoprazole 30mg for the healing of erosive esophagitis and resolution of heartburn.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Local Institution
Seoul, South Korea
Start Date
July 1, 2010
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
January 12, 2012
292
ACTUAL participants
Ilaprazole
DRUG
Lansoprazole
DRUG
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
NCT07310927
NCT06953986
NCT06241183
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions